

# PLA2G6-ASSOCIATED NEURODEGENERATION (PLAN): CHARACTERIZATION OF PATIENTS AND DRUG SCREENING.

Diana Reche López(1,\*), Irene Villalon(1) y José A. Sánchez Alcázar(2)  
Centro Andaluz de Biología del Desarrollo (CABD) Ctra. De Utrera KM 1.  
Universidad Pablo de Olavide, Sevilla.

## OBJETIVES


In the current work we studied the pathophysiology of three confirmed cases of PLAN using fibroblasts derived from the patients: PLAN 10 (heterozygous mutation), PLAN 11 (heterozygous mutation) and PLAN 8 (homozygous mutation). The aim of this study is to characterize, in patient-derived fibroblasts, the pathological alterations produced by mutations in PLA2G6.

## INTRODUCTION


Neurodegeneration with brain iron accumulation (NBIA) involve a group of rare neurodegenerative disorders characterized by brain iron accumulation, progressive extrapyramidal dysfunction (dystonia, stiffness, choreoathetosis), and presence of axonal spheroids, usually limited by the central nervous system.

Within the different subtypes of NBIA, in this study we focussed in PLA2G6-associated neurodegeneration (PLAN), diseases caused by a mutation in the phospholipase A2 group VI (PLA2G6). PLA2G6 encodes the enzyme iPLA2b, a calcium-independent phospholipase A2 which is involved in lipid metabolism. The loss of iPLA2b's function result in mitochondrial abnormalities and synaptic transmission impairment in neurons among other alterations.

## RESULTS



**Figure 1.** Western Blot analysis of PLA2G6, Ferritin, LC3B, NCOA4 and Actin in control and patients cultured fibroblasts.



**Figure 2.** Prussian Blue staining in control and patients cultured fibroblasts

## CONCLUSIONS

Our results confirm iron accumulation in patients-derived fibroblasts, impaired autophagy and ferritinophagy, especially in fibroblasts from patient that suffers the homozygous mutation (Plan 8). The purpose is to carry out a drug screening able to reverse the pathophysiology observed

## BIBLIOGRAPHY

1. Guo YP, Tang BS, Guo JF. PLA2G6-Associated Neurodegeneration (PLAN): Review of Clinical Phenotypes and Genotypes. *Front Neurol.* 2018;9:1100. Published 2018 Dec 18.
2. Gregory A, Hayflick SJ. Neurodegeneration with brain iron accumulation. *Folia Neuropathol.* 2005;43(4):286–296.
3. Khateeb S, Flusser H, Ofir R, et al. PLA2G6 mutation underlies infantile neuroaxonal dystrophy. *Am J Hum Genet.* 2006;79(5):942–948.

## Prussian Blue stain quantification

